What is Deka Biosciences?
Headquartered in Germantown, Maryland, Deka Biosciences is a precision medicine company dedicated to the discovery and development of innovative therapies for cancer and inflammatory diseases. The company leverages a unique, data-driven approach to engineer cytokine-based therapeutics, aiming to maximize efficacy while minimizing systemic toxicity. By focusing on the intersection of immunology and oncology, Deka Biosciences is positioning itself at the forefront of biopharmaceutical innovation, addressing critical unmet needs for patients worldwide. Their strategic focus on targeted delivery mechanisms distinguishes them within the crowded biotech sector, offering a scalable solution for complex disease management.
How much funding has Deka Biosciences raised?
Deka Biosciences has raised a total of $40M across 2 funding rounds:
Series A
$20M
Series B
$20M
Series A (2021): $20M with participation from Bayer
Series B (2023): $20M led by Lumira Ventures and MPM BioImpact
Key Investors in Deka Biosciences
Bayer
Bayer is a global life science enterprise with core competencies in healthcare and agriculture, focusing on innovative pharmaceuticals and biotechnology traits to improve human health.
Lumira Ventures
Lumira Ventures is a prominent life sciences venture capital firm that partners with mission-driven entrepreneurs to commercialize impactful healthcare products and medical innovations.
MPM BioImpact
MPM BioImpact is an investment firm that manages early-stage and impact funds, dedicated to converting cutting-edge scientific research into life-saving therapeutics.
What's next for Deka Biosciences?
With the successful closure of its latest financing round, Deka Biosciences is well-positioned to advance its lead candidates through critical clinical milestones. The strategic roadmap likely involves scaling manufacturing capabilities, expanding internal research and development teams, and initiating further human trials to validate the therapeutic potential of its platform. As the company matures, the focus will shift toward establishing long-term commercial viability and exploring potential partnerships with global pharmaceutical entities to bring its pipeline to market. The continued support from top-tier venture capital firms and industry leaders suggests a clear path toward becoming a significant contributor to the future of precision medicine and patient-centric healthcare solutions.
See full Deka Biosciences company page
